Integral Molecular’s Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors
Philadelphia –Integral Molecular, a leader in antibody discovery against membrane proteins, is pleased to announce that its out-licensed anti-Claudin 6 (CLDN6) bispecific antibody, CTIM-76, […]